Literature DB >> 8310211

Primary antiphospholipid antibody syndrome and cerebral ischemia: report on acute intervention in two cases and literature review with emphasis on therapeutic options.

S Braune1, R Siekmann, P Vaith, C H Lücking.   

Abstract

In two patients with primary antiphospholipid antibody syndrome and acute cerebrovascular ischemic events, local intraarterial fibrinolysis and intravenous heparin therapy, respectively, resulted in a limitation of persisting neurological deficits. On the basis of the 35 case reports available a combination of anticoagulation with warfarin, plus immunosuppression with steroids and/or cyclophosphamide or azathioprine, appears to be the best treatment to prevent further cerebral ischemic events. The therapeutic options are reviewed and discussed.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8310211     DOI: 10.1007/BF00301266

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  36 in total

1.  Plasma exchange and the anticardiolipin syndrome in pregnancy.

Authors:  D Fulcher; G Stewart; T Exner; B Trudinger; R Jeremy
Journal:  Lancet       Date:  1989-07-15       Impact factor: 79.321

2.  The laboratory heterogeneity of lupus anticoagulants.

Authors:  D A Triplett; J T Brandt; R L Maas
Journal:  Arch Pathol Lab Med       Date:  1985-10       Impact factor: 5.534

3.  Cerebrovascular and neurologic disease associated with antiphospholipid antibodies: 48 cases.

Authors:  S R Levine; M J Deegan; N Futrell; K M Welch
Journal:  Neurology       Date:  1990-08       Impact factor: 9.910

4.  Risk of recurrent thromboembolic events in patients with focal cerebral ischemia and antiphospholipid antibodies. The Antiphospholipid Antibodies in Stroke Study Group.

Authors:  S R Levine; R L Brey; C L Joseph; S Havstad
Journal:  Stroke       Date:  1992-02       Impact factor: 7.914

5.  Primary antiphospholipid syndrome (PAPS). Two case reports and therapeutic implications.

Authors:  J A Rump; B Lang; H Engler; H H Peter
Journal:  Rheumatol Int       Date:  1991       Impact factor: 2.631

6.  Cyclophosphamide use in a young woman with antiphospholipid antibodies and recurrent cerebrovascular accident.

Authors:  M C Perez; W A Wilson; E Scopelitis
Journal:  South Med J       Date:  1989-11       Impact factor: 0.954

7.  Evaluation of the anti-cardiolipin antibody test: report of an international workshop held 4 April 1986.

Authors:  E N Harris; A E Gharavi; S P Patel; G R Hughes
Journal:  Clin Exp Immunol       Date:  1987-04       Impact factor: 4.330

8.  Recurrent ischemic attacks in two young adults with lupus anticoagulant.

Authors:  G Landi; M V Calloni; M Grazia Sabbadini; P Mannuccio Mannucci; L Candelise
Journal:  Stroke       Date:  1983 May-Jun       Impact factor: 7.914

9.  Neurological disease associated with antiphospholipid antibodies.

Authors:  D P Briley; B M Coull; S H Goodnight
Journal:  Ann Neurol       Date:  1989-03       Impact factor: 10.422

10.  Lupus anticoagulant: an analysis of the clinical and laboratory features of 219 cases.

Authors:  D A Gastineau; F J Kazmier; W L Nichols; E J Bowie
Journal:  Am J Hematol       Date:  1985-07       Impact factor: 10.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.